Maxim analyst Jason McCarthy downgraded Amryt Pharma to Hold from Buy.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AMYT:
- Amryt Pharma downgraded to Neutral from Overweight at Cantor Fitzgerald
- Chiesi Farmaceutici S.p.A. to acquire Amryt Pharma
- Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
- Amryt Pharma announces results from Phase 3 pediatric trial of lomitapide
- Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH